Validation of a new immunoenzymatic method to detect antibodies to RNA polymerase III in systemic sclerosis

Clin Exp Rheumatol. 2007 May-Jun;25(3):373-7.

Abstract

Objective: To test the reliability of a new enzyme-linked immunosorbent assay (ELISA) to identify anti-RNA polymerase III (RNAP III) positive sera from Italian patients with Systemic Sclerosis (SSc) and other chronic inflammatory disorders.

Methods: A comparison between the new ELISA for anti-RNAP III and the gold standard technique, immunoprecipitation (IP), was first performed on 106 SSc patients, 16 patients with other connective tissue diseases and 10 healthy subjects. A further ELISA evaluation was performed on 224 SSc patients, 120 subjects with other rheumatic or infectious diseases, and 81 healthy controls.

Results: Plotting ELISA and IP data in a Receiver Operator Characteristic curve, the ELISA cut-off value providing the best specificity (99.1%) and sensibility (100%) was 28 U/ml (AUC=0.999; p<0.0001). Using this cut-off in the second analysis, anti-RNAP III positive results were found in 41 (18.3%) SSc patients, all negative for anticentromere or anti-topoisomerase I antibodies, while only 3 subjects tested positive among the 120 sera collected from other patients. All the healthy subjects were negative.

Conclusion: This new ELISA for anti-RNAP III is highly accurate when a proper cut-off value is employed and represents a valid substitute to IP in a clinical setting.

Publication types

  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies / blood*
  • Enzyme-Linked Immunosorbent Assay / methods*
  • Humans
  • Immunoprecipitation / methods
  • Italy
  • Middle Aged
  • RNA Polymerase III / immunology*
  • ROC Curve
  • Reference Values
  • Reproducibility of Results
  • Scleroderma, Systemic / blood
  • Scleroderma, Systemic / ethnology
  • Scleroderma, Systemic / immunology*
  • Sensitivity and Specificity

Substances

  • Antibodies
  • RNA Polymerase III